title: Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.
abstract: BACKGROUND
  Prospective, observational studies that enroll large numbers of patients with few exclusion criteria may better reflect actual ongoing clinical experience than randomized clinical trials. Our purpose was to obtain efficacy and safety information from a cohort of subjects exposed to latanoprost/timolol fixed combination (FC) for ≥18 months using a prospective, observational design.
  
  
  METHODS
  In all, 577 office-based ophthalmologists in Germany switched 2339 patients with glaucoma or ocular hypertension to latanoprost/timolol FC for medical reasons. Follow-up visits were scheduled for every 6 months over 24 months; physicians followed usual care routines. Intraocular pressure (IOP), visual field status, optic nerve head findings, and adverse events were recorded. Efficacy parameters were evaluated for the per protocol (PP) population; the safety population included subjects receiving ≥1 drop of FC. Physicians rated efficacy, tolerability, and subject compliance at month 24.
  
  
  RESULTS
  Of the 2339 subjects switched to latanoprost/timolol FC (safety population), the primary reasons for switching were inadequate IOP reduction (78.2%) and desire to simplify treatment with once-daily dosing (29.4%; multiple reasons possible). In all, 1317 (56.3%) subjects completed the study, and 1028 (44.0%) were included in the PP population. Most discontinuations were due to loss to follow-up. Change in mean IOP from baseline to month 6 was -4.0 ± 4.31 mmHg, a reduction that was maintained throughout (P < 0.05 for change at all time points). By investigator assessments, optic disc parameters and visual field were stable over 24 months, and there was no relationship between IOP reduction over 24 months and development of a visual field defect. More than 90% of physicians rated latanoprost/timolol FC as "very good" or "good" for efficacy (PP population), tolerability, and compliance. The FC was safe and well tolerated. No change in iris color was reported by most subjects (83.1%) at month 24.
  
  
  CONCLUSIONS
  Over 24 months, latanoprost/timolol FC effectively lowers IOP levels and is well tolerated in patients with glaucoma or ocular hypertension who change from their previous ocular hypotensive therapy for medical reasons. Investigator assessments found optic disc parameters and visual field to be stable throughout 24 months of follow-up.
authors.affiliation: Bürgerhospital Frankfurt am Main, Augenklinik, Frankfurt am Main, Germany. o.schwenn@burgerhospital-ffm.de
authors.forename: Oliver
authors.initials: O
authors.lastname: Schwenn
authors.forename: Barbara
authors.initials: B
authors.lastname: Heckmann
authors.forename: Claudia
authors.initials: C
authors.lastname: Guzy
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Miller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage*; D016896:Treatment Outcome; D014794:Visual Fields / Q000187:drug effects; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol
references.citation: Br J Ophthalmol. 1995 Jan;79(1):12-6
references.pmid: 7880782
references.citation: Am J Ophthalmol. 2007 Oct;144(4):533-40
references.pmid: 17686450
references.citation: Adv Ther. 2007 Mar-Apr;24(2):376-86
references.pmid: 17565929
references.citation: Graefes Arch Clin Exp Ophthalmol. 2002 Nov;240(11):893-9
references.pmid: 12486510
references.citation: J Glaucoma. 2003 Oct;12(5):393-8
references.pmid: 14520147
references.citation: Am J Ophthalmol. 1998 Oct;126(4):498-505
references.pmid: 9780094
references.citation: Arch Ophthalmol. 1978 Nov;96(11):2045-8
references.pmid: 363105
references.citation: Ophthalmology. 2004 Feb;111(2):276-82
references.pmid: 15019375
references.citation: Arch Ophthalmol. 2002 Oct;120(10):1268-79
references.pmid: 12365904
references.citation: J Ocul Pharmacol Ther. 2009 Apr;25(2):145-52
references.pmid: 19284321
references.citation: Am J Ophthalmol. 2000 Oct;130(4):429-40
references.pmid: 11024415
references.citation: Arch Ophthalmol. 2006 Apr;124(4):471-6
references.pmid: 16606871
references.citation: Invest Ophthalmol Vis Sci. 1977 Jul;16(7):623-4
references.pmid: 873723
references.citation: J Glaucoma. 1999 Feb;8(1):24-30
references.pmid: 10084271
references.citation: Arch Ophthalmol. 2010 Feb;128(2):165-72
references.pmid: 20142538
references.citation: Ophthalmic Surg. 1995 May-Jun;26(3):233-6
references.pmid: 7651690
references.citation: Arch Ophthalmol. 2003 Jan;121(1):48-56
references.pmid: 12523884
references.citation: Br J Ophthalmol. 1994 Dec;78(12):899-902
references.pmid: 7819171
references.citation: Br J Ophthalmol. 2004 Oct;88(10):1295-8
references.pmid: 15377554
references.citation: Arch Ophthalmol. 2002 Jul;120(7):915-22
references.pmid: 12096962
references.citation: Am J Ophthalmol. 1987 Feb 15;103(2):188-93
references.pmid: 3812621
references.citation: Br J Ophthalmol. 2009 Dec;93(12):1572-5
references.pmid: 19628493
references.citation: Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
references.pmid: 12049574
references.citation: Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20
references.pmid: 19038618
references.citation: Br J Ophthalmol. 2004 Feb;88(2):199-203
references.pmid: 14736774
references.citation: Ophthalmology. 2006 Jan;113(1):70-6
references.pmid: 16263174
references.citation: Am J Public Health. 1993 May;83(5):711-6
references.pmid: 8484454
references.citation: Ophthalmology. 1991 Jul;98(7):1079-82
references.pmid: 1891217